Lund 2022: Invited speakers and scholars

Invited Speakers and Scientific Committee

Sonja Aits

Bo Bernhardsson

Petter Brodin

Ana Carneiro

Ana Carneiro is a medical oncologist, who works with a multidisciplinary team of medical oncologists, surgeons, dermatologists, and pathologists to treat patients with melanomas.

Ana is also involved in a variety of clinical trials, ranging from First in Human to Phase III, and encompassing different tumor types/diagnoses. Ana serves as Medical Lead (Medical Director) of the Oncology Clinical Trials Unit and Early Phase Trials Unit at Skane University Hospital in Lund, Sweden.

An Associate Professor and co-lead of the Network for Drug Development and Clinical Trials of the Lund University Cancer Centre, Ana’s research interests primarily lie in the field of melanoma, immunotherapy of cancer and immune related side-effects. Ana regularly collaborates in several research projects with the Lund Melanoma Study Group and with the Melanoma Lab.

Thoas Fioretos

Thoas Fioretos is a professor and senior consultant at the Department of Clinical Genetics, Lund University, Sweden. He is also the Director of national Clinical Genomics platform at SciLifeLab, a national facility offering expertise and service in next-generation sequencing for clinical research and developing new diagnostic assays for improved precision diagnostics. Professor Fioretos is  also a recipient of a Wallenberg Clinical Scholar.  

His research is focused on translating genomic discoveries in acute leukemia into improved clinical decision-making and new therapies. Fioretos is a founding member of Genomic Medicine Sweden, aiming at implementing genomics-based precision medicine in Sweden, and is the co-coordinator of the Hematology Working Group within GMS. He has published >120 research articles, many in top tier journals, and is an Associate Editor of Genes Chromosomes and Cancer. Fioretos has co-founded two spin-out companies active in bioinformatics (Qlucore AB) and antibody-based therapies of cancer (Cantargia AB), respectively. 

Magnus Fontes

Magnus Fontes is General Manager of Institut Roche in Paris, France. Fontes is PhD in Mathematics and an expert in bioinformatics, machine learning and mathematical & statistical modeling focused on the analysis and visualization of complex biomedical systems. His publications over the last decades cover cancer and infectious disease building on novel theoretical mathematical methods and algorithms.

Fontesindustrial and academic experience include e.g. 20032014: Head of the Centre for Mathematical Sciences at Lund University, Lund, Sweden, 20142017: Director at the Centre for Bioinformatics,Biostatistics and Integrative Biology (C3BI), Institut Pasteur, Paris, France. 20182020 PrincipalScientist and Head of Systems Cancer Immunology, Cancer Immunology, Genentech, South San Francisco, CA, USA.

Fontes is Cofounder and member of the board of the bioinformatics software company Qlucore

Samuel Isaacson

Samuel Isaacson received his Sc.B. from Brown University, and Ph.D. from the Courant Institute at New York University. After a postdoc in the mathematical biology group at the University of Utah he joined the Department of Mathematics and Statistics at Boston University, where he is currently a Professor. He research spans mathematical biology, systems biology, biophysics, numerical analysis, and scientific computing.

Recent research interests include studying how cells can signal robustly in the presence of noisy, spatially heterogeneous environments; investigating mechanisms that can control the initiation of T cell signaling; developing numerical methods for simulating stochastic reaction-diffusion systems; and deriving rigorous coarse grained approximations to such models.

Karin Leandersson

Karin Leandersson holds a M.Sc. in Biochemistry and a B.Sc. in Biology from the Natural Science faculty, Lund University, Sweden. She continued studying Immunology and received a PhD in Immunology at the Medical Faculty in 2002. During her PostDoc 2002-2007 she changed field now working on breast cancer and cancer biology.

In 2007 Karin Leandersson became an Associate Professor in Immunology, and started her own group with a focus on human Tumor Immunology. Since 2017 Karin Leandersson is Professor in Human Tumor Immunology at the medical faculty Lund University, Sweden. Her research interest is the human immune system and its mutual interaction with cancer, with a focus on primary human tissues and immune cells, with an aim to be able to understand tumor immunology better in the human perspective. 

Kevin Litchfield

Adam MacLean

Adam MacLean is an Assistant Professor in the Department of Quantitative and Computational Biology at the University of Southern California. Adam studied mathematical physics at the University of Edinburgh, then completed his PhD in systems biology from Imperial College London. He worked as a postdoc at the University of Oxford and the University of California, Irvine, before joining USC in 2019.

Adam’s lab at USC seeks to understand how cell fate decisions regulate tissues and organs during development, homeostasis, and cancer. These questions are addressed via the development of new mathematical models and machine learning tools, drawing on recent biological advances in single-cell measurement technologies, and computational advances in Julia for numerical systems biology. His work has appeared in PNAS, Stem Cells, and Cancer Research. He has won multiple fellowships and awards, including an NSF CAREER Award in 2021.

Ira Mellman

Ira Mellman came to Genentech in 2007 after more than 20 years as a faculty member at the Yale University School of Medicine, where he was chair of his department, a member of the Ludwig Institute for Cancer Research, scientific director of the Yale Cancer Center, and Sterling Professor of Cell Biology and Immunobiology. Dr. Mellman has an AB from Oberlin College & Conservatory and a PhD in Genetics from Yale, and was a Fellow at the Rockefeller University with Ralph Steinman. Dr. Mellman’s laboratory is known not only for advances in fundamental cell biology in the area of membrane traffic (notably, the discovery of endosomes) and for applying these insights to understanding the cellular basis of the immune response. 

Of particular importance to cancer immunotherapy have been his laboratory’s pioneering contributions to elucidating how dendritic cells initiate immunity or maintain immune tolerance.  Recently, his group has turned to elucidating how T cell signaling is regulated by immune checkpoints, and how personalized cancer vaccines and cell-based therapies can be used to enhance anti-tumor T cell responses.  Ira ran all of oncology research at Genentech until the end of 2013 when he decided to concentrate his efforts on cancer immunotherapy and became Vice President of Cancer Immunology.  His group was responsible for having brought Genentech’s anti-PD-L1 antibody, Tecentriq® (atezolizumab), to the clinic, an approved blockbuster drug for a growing list of indications including bladder, triple negative breast cancer, small cell lung cancer, and non-small cell lung cancer. Ira also oversaw the discovery and early development of cancer vaccine programs directed against patient-specific mutant neo-antigens using mRNA (in collaboration with BioNTech; now in Phase II) and DNA (in collaboration with Vaccibody) based platforms, tiragolumab (anti-TIGIT, now in pivotal trials), Cotellic® (MEK inhibitor cobimetinib), mosunetuzumab (anti-CD20/CD3 bispecific, now in pivotal trials), and ipatasertib (Akt inhibitor). 

Ira is a member of the US National Academy of Sciences, American Academy of Arts & Sciences, the European Molecular Biology Organization, and the former Editor in Chief of the Journal of Cell Biology.  He has also served on the editorial boards of Cell, the Journal of Experimental Medicine, EMBO Journal, OncoImmunology among others, and is the recipient of many named lectureships, honorary professorships, and awards, including Yale University’s Wilbur Lucius Cross medal and the 2019 Leadership Award in Cancer Immunology from the American Association for Precision Medicine.  He has also served on the boards of AACR, SITC, the ASCB, the Melanoma Research Foundation, and the Cancer Research Institute.  

Ira also remains an ex-musician and frustrated composer and songwriter whose most recent work explores the underinvestigated genre of “bio-rock”.   

Christopher Rackauckas

Chris’ research is Scientific Machine Learning (SciML): the integration of domain models with artificial intelligence techniques like machine learning. By using the structured scientific (differential equation) models together with the unstructured data-driven models of machine learning, our simulators can be accelerated, our science can better approximate the true systems, all while enjoying the robustness and explainability of mechanistic dynamical models. 

Chris is the lead developer of the DifferentialEquations.jl solver suite along with hundreds of other Julia packages, earning him the inaugural Julia Community Prize and front page features on many tech community sites. Chris’ work on high performance differential equation solving is the engine accelerating many applications from the MIT-CalTech CLiMA climate modeling initiative to the SIAM Dynamical Systems award winning DynamicalSystems.jl toolbox. He is the lead developer of JuliaSim, where the work is credited for the 15,000x acceleration of NASA Launch Services simulations and recently demonstrated a 60x-570x acceleration over Modelica tools in HVAC simulation. For these achievements Chris received the US Air Force Artificial Intelligence Accelerator Scientific Excellence Award. As lead developer of Pumas, he received the ISoP Mathematical and Computational Special Interest Group Award at the American Conference of Pharmacology (ACoP) 2019 for his work on improved clinical dosing via Koopman Expectations, along with the ACoP 2020 Quality Award for his work with Pfizer on GPU-accelerated quantitative systems pharmacology to accelerate preclinical analysis by 175x. Notably, Moderna adopted Pumas in 2020 to accelerate crucial clinical trials, noting “Pumas has emerged as our ‘go-to’ tool for most of our analyses in recent months”. For these achievements, Chris received the Emerging Scientist award from ISoP, the highest early career award in pharmacometrics. 

Anders Rantzer

Thomas B. Schön

Thomas B. Schön is the Beijer Professor of Artificial Intelligence in the Department of Information Technology at Uppsala University. He has held visiting positions with the University of Cambridge (UK), the University of Newcastle (Australia) and Universidad Técnica Federico Santa Maria (Valparaiso, Chile). In 2018, he was elected to The Royal Swedish Academy of Engineering Sciences (IVA) and The Royal Society of Sciences at Uppsala. He received the Tage Erlander prize for natural sciences and technology in 2017 and the Arnberg prize in 2016, both awarded by the Royal Swedish Academy of Sciences (KVA). He is a fellow of the ELLIS society. 

Kristian Soltesz

Kristian Soltesz is associate professor with the Department of Automatic Control, Lund University, since 2019. He received the M.Sc. and Ph.D. degrees in Automatic Control in 2008 and 2013, both from Lund University. His research interests span various topics within medical control systems. 

Eduardo Sontag

Eduardo Sontag’s major current research interests lie in several areas of control and dynamical systems theory, systems molecular biology, synthetic biology, computational biology, and cancer and immunology. He received his Licenciado degree from the Mathematics Department at the University of Buenos Aires in 1972, and his Ph.D. (Mathematics) under Rudolf E. Kalman at the University of Florida, in 1977.

From 1977 to 2017, he was with the Department of Mathematics at Rutgers, The State University of New Jersey, where he was a Distinguished Professor of Mathematics as well as a Member of the Graduate Faculty of the Department of Computer Science and the Graduate Faculty of the Department of Electrical and Computer Engineering, and a Member of the Rutgers Cancer Institute of NJ. In addition, Dr. Sontag served as the head of the undergraduate Biomathematics Interdisciplinary Major, Director of the Center for Quantitative Biology, and Director of Graduate Studies of the Institute for Quantitative Biomedicine.

In January 2018, Dr. Sontag was appointed as a University Distinguished Professor in the Department of Electrical and Computer Engineering and the Department of BioEngineering at Northeastern University.  Since 2006, he has been a Research Affiliate at the Laboratory for Information and Decision Systems, MIT, and since 2018 he has been a member of the Faculty in the Program in Therapeutic Science at Harvard Medical School. 

Eduardo Sontag has authored over five hundred research papers and monographs and book chapters in the above areas with over 47,000 citations and an h-index of 97.   He is in the Editorial Board of several journals, including:  Cell Systems,  IET Proceedings Systems Biology, Synthetic and Systems Biology, International Journal of Biological Sciences, and Journal of Computer and Systems Sciences, and is a former Board member of SIAM Review, IEEE Transactions in Automatic Control, Systems and Control Letters, Dynamics and Control, Neurocomputing, Neural Networks, Neural Computing Surveys, Control-Theory and Advanced Technology, Nonlinear Analysis: Hybrid Systems, and Control, Optimization and the Calculus of Variations. In addition, he is a co-founder and co-Managing Editor of the Springer journal MCSS (Mathematics of Control, Signals, and Systems).

He is a Fellow of various professional societies: IEEE, AMS, SIAM, and IFAC, and is also a member of SMB and BMES. He has been Program Director and Vice-Chair of the Activity Group in Control and Systems Theory of SIAM, and member of several committees at SIAM and the AMS, including Chair of the Committee on Human Rights of Mathematicians of the latter in 1981-1982. He was awarded the Reid Prize in Mathematics in 2001, the 2002 Hendrik W. Bode Lecture Prize and the 2011 Control Systems Field Award from the IEEE, the 2002 Board of Trustees Award for Excellence in Research from Rutgers, and the 2005 Teacher/Scholar Award from Rutgers.  

Visiting Scholars

Artur Mezheyeuski

Artur Mezheyeuski holds an MD and a PhD. Current affiliation Dept of Immunology, Genetics and Pathology, Uppsala University, Sweden. 
Born in Riga, Latvia and performed medical education (MD) and training at Riga’s Stradina University (Riga, Latvia) and later in Belarusian State Medical University (Minsk, Belarus) where Artur became a specialist in pathology in 2008.

Supported by an exchange grant, Artur conducted PhD training at the Karolinska Institute, Sweden, where he focused on the analyses of malignant tissue and its elements. After PhD training Artur extended his efforts of spatial tissue analysis into tumour immunology. Artur have set up a state-of-the-art multi-marker immunofluorescence method at host department and developed an analytical pipeline to address the spatial aspects and to evaluate cell-to-cell interaction and neighbouring patterns of different immune cell subclasses.

Artur have founded a Sweden-registered company providing pathology and image-analysis expertise for R&D (HistoOne AB). Research interest: the implementation of high-resolution spatial tissue analysis, with a special focus on tumor immunology. 

Solveig van der Vegt

Solveig van der Vegt is a fourth-year PhD student at the Wolfson Centre for Mathematical Biology at the University of Oxford. Solveig graduated from Cornell University in 2018 with a BA in Biological Sciences with a minor in Mathematics. She is now combining these two fields in her PhD research. The main project focuses on modeling autoimmune myocarditis and the effects of immune checkpoint inhibitors on the development and progression of this disease. 

MieLu McDermott

Meghan Ferrall-Fairbanks

Meghan Ferrall-Fairbanks, Ph.D. is an Assistant Professor of Biomedical Engineering in the J. Crayton Pruitt Family Department of Biomedical Engineering at the University of Florida (UF). Dr. Ferrall-Fairbanks received her Bachelor of Science degree in Mechanical Engineering with a biomechanics minor from UF in 2012. She earned her Ph.D. in the joint Department of Biomedical Engineering at Georgia Tech and Emory University in 2017. Her dissertation research focused on integrating wet-lab experiments and computational methods to tease apart complex enzyme-on-enzyme interactions in proteolytic networks up-regulated in tissue destructive diseases. 

Following her time in Atlanta, Dr. Ferrall-Fairbanks was an Applied Postdoctoral Fellow in the Department of Integrated Mathematical Oncology at Moffitt Cancer Center and Research Institute. Her research at Moffitt focused on using mathematical modeling to study single-cell heterogeneity and clonal dynamics in cancer; while there she worked on multi-disciplinary projects, with modelers, basic scientists, and clinicians addressing top questions in cancer research. Dr. Ferrall-Fairbanks’ current research focuses on using quantitative biology approaches to cultivate a mechanistic understanding of tumor heterogeneity and evolution to optimize cancer treatment strategies. Ecology and evolutionary forces in cancer allows a tumor to alter its growth and metastasis. The Battling Evolution through Adaptive Therapies (BEAT) Cancer Lab integrates computational, mathematical, and wet-lab experimental techniques to investigate tumor heterogeneity at the molecular, tissue, and systems levels.  

On-site contact persons

 

Eva Westin

+46 46 222 87 87
eva.westin@control.lth.se

Kristian Solstesz

+46 46 222 87 77
 kristian.soltesz@control.lth.se